^
    over2years
    Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer. (PubMed, Cancer Chemother Pharmacol)
    PF-06881894 as a single 3- or 6-mg dose prior to definitive surgery, or multiple 6-mg/cycle doses postoperatively, with/without myelosuppressive chemotherapy, was consistent with the clinical pharmacology and safety profile of reference pegfilgrastim.
    Clinical • P1/2 data • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal
    |
    CD34 (CD34 molecule)
    |
    Neulasta (pegfilgrastim) • Nyvepria (pegfilgrastim-apgf)